Sun Pharma’s ILUMYA gets US FDA review nod for psoriatic arthritis use

The pharma firm added that ILUMYA has received marketing authorisation from more than 55 health authorities worldwide since its original approval, including in India, Japan, the European Union, China, Australia and Canada.

Leave a Reply

Your email address will not be published. Required fields are marked *